{"product_id":"poai-vrio-analysis","title":"Predictive Oncology Inc. (POAI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Predictive Oncology Inc. (POAI) truly built to last? This VRIO analysis cuts straight to the core, dissecting whether its key resources are Valuable, Rare, Inimitable, and Organized to forge a sustainable competitive advantage. Discover the definitive answer to how Predictive Oncology Inc. (POAI) maintains its edge - dive in below to see the full strategic breakdown.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e1. PEDAL AI Platform with CORE Active Learning\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re analyzing a core asset that sits at the intersection of biotech and deep tech, which is a tricky spot to value right now, especially given Predictive Oncology Inc.'s recent strategic pivot. The PEDAL AI Platform, powered by CORE Active Learning, is the engine for their drug discovery claims, and we need to assess if it provides a durable edge.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Drives Drug Discovery Efficiency\u003c\/h3\u003e\n\u003cp\u003eThe platform clearly delivers value by cutting down on expensive, slow lab work. It drives drug discovery by predicting tumor response to compounds with a reported 92% accuracy. Honestly, this level of precision is what pharma partners pay for. Case studies show this capability can lead to up to an 87% cost reduction in developing accurate predictive models, which is a massive saving in the multi-billion dollar drug development landscape.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the platform’s impact metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePredictive Accuracy for Tumor Response: \u003cstrong\u003e92%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMax. Experimentation Cost Reduction: \u003cstrong\u003e87%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTime to Preclinical Candidate Acceleration: Up to 3x faster\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Patented Iterative Guidance\u003c\/h3\u003e\n\u003cp\u003eThe rarity here isn't just using AI; it's the specific methodology. The CORE (Computational Research Engine) Active Learning approach is patented and relatively unique in how it iteratively guides wet-lab experimentation to be the most informative for improving the predictive model. Most in silico methods just predict outcomes; CORE actively tells you which experiment to run next.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier to Replication\u003c\/h3\u003e\n\u003cp\u003eReplicating this is tough, so the imitability is high. It’s not just about the code; it’s the combination of the specific, complex algorithms and their integration with Predictive Oncology Inc.'s proprietary data sets - like their biobank of over 150,000 tumor samples. Building that data moat takes years and significant capital, making direct copying a defintely long shot for competitors.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Centralized Support and Capitalization\u003c\/h3\u003e\n\u003cp\u003ePredictive Oncology Inc. appears organized to exploit this asset, though the recent financial structure is complex. The platform is central to their R\u0026amp;D pipeline, and the organization recently secured significant backing to support its computational needs. This is evidenced by the recent capital raise, which involved approximately $50.8 million in cash and an additional notional value of about $292.7 million in ATH tokens, totaling a strategic infusion of roughly $343.5 million to support their AI infrastructure.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the recent Q3 2025 financial stress; they ended the quarter with only $181,667 in cash from continuing operations, and the derivative liability related to the digital asset strategy pushed the net loss to $77.7 million.\u003c\/p\u003e\n\u003cp\u003eThe VRIO scoring for this core resource looks like this:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (1-4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes, significant cost\/time savings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes, patented iterative guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly to Imitate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes, supported by recent capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary Edge\u003c\/h3\u003e\n\u003cp\u003eThe resulting advantage is currently a \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e. While the patent and data moat provide a buffer, AI model superiority is always at risk of being surpassed by faster-moving competitors or new foundational models. The iterative feedback loop from their drug discovery work is their best bet to sustain this edge, but it’s not guaranteed to last forever.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e2. Vast Biobank of Tumor Samples\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe biobank is a core tangible asset underpinning POAI's AI-driven drug discovery strategy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the essential, high-quality, diverse, assay-capable data input needed to train and validate their AI models, exceeding \u003cstrong\u003e150,000\u003c\/strong\u003e heterogenous human tumor samples.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while many firms have biobanks, the sheer size and assay-capability of this specific, live-cell collection is hard to match quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High, due to the time and cost required to ethically collect and process this volume of unique biological material.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the biobank directly feeds the PEDAL platform, creating a clear, exploited synergy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the physical asset and the data it generates are a long-term moat.\u003c\/p\u003e\n\n\u003cp\u003eThe scale and validation of the biobank provide a quantifiable advantage:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset Metric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003cth\u003eContext\/Validation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Tumor Specimens\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e150,000\u003c\/strong\u003e+\u003c\/td\u003e\n\u003ctd\u003eHeterogenous live cell tumor samples spanning \u003cstrong\u003e137\u003c\/strong\u003e cancer indications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology Slides\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200,000\u003c\/strong\u003e+\u003c\/td\u003e\n\u003ctd\u003eAssociated data assets supporting AI model training.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLongitudinal Data History\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e Years\u003c\/td\u003e\n\u003ctd\u003eActionable drug and tumor response data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCryopreservation Stability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e Concordance\u003c\/td\u003e\n\u003ctd\u003eRate between original fresh testing and long-term stored samples.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Prediction Accuracy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAccuracy rate of the PEDAL platform in predicting tumor response to drug compounds.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe integration of the biobank with the proprietary platform highlights organizational exploitation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe biobank of over \u003cstrong\u003e150,000\u003c\/strong\u003e assay-capable heterogenous human tumor samples is paired with the AI\/ML platform, PEDAL.\u003c\/li\u003e\n\u003cli\u003eThe PEDAL platform leverages this data to make drug-response predictions, demonstrated in a Proof of Concept study testing \u003cstrong\u003e175\u003c\/strong\u003e FDA-approved drugs against \u003cstrong\u003e130\u003c\/strong\u003e ovarian tumor samples.\u003c\/li\u003e\n\u003cli\u003eThe biobank's data supports the company's position in the expanding global biospecimen market, valued at \u003cstrong\u003e$4.4 billion\u003c\/strong\u003e in 2023 and projected to reach \u003cstrong\u003e$11.7 billion\u003c\/strong\u003e by 2031.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e3. CLIA Certified Laboratory Facility\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe CLIA Certified Laboratory Facility allows for in-house, quality-controlled in vitro testing, such as the ChemoFx® assay, which generates proprietary data supporting regulatory compliance for clinical applications. The PEDAL platform, which utilizes this data, reportedly predicts with 92% accuracy if tumor samples will respond to specific drug compounds.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for in-house, quality-controlled in vitro testing (like ChemoFx®) that generates proprietary data, ensuring regulatory compliance for clinical applications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many biotech firms have CLIA labs, but it’s a necessary operational component, not a differentiator on its own.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; facilities and certifications can be replicated with capital investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; it directly supports the validation loop for the PEDAL platform and ChemoFx® assay.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as it’s a standard operational resource that doesn't create unique economic value alone.\u003c\/p\u003e\n\u003cp\u003eThe facility supports the ChemoFx® drug response assay, which will initially focus on ovarian and other gynecological cancers. The company maintains an extensive biorepository of over 150,000 assay-capable heterogenous human tumor samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110,310\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025 (Q1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,682\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025 (Q2)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,618\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025 (Q3)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities of Continuing Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational context includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PEDAL platform accuracy is reported at 92%.\u003c\/li\u003e\n\u003cli\u003eThe biobank size is over 150,000 tumor samples.\u003c\/li\u003e\n\u003cli\u003eStockholders' deficit was $77.4 million as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e4. ChemoFx® Drug Response Assay\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOffers oncologists a treatment selection marker, initially for gynecologic cancers, providing a direct, near-term revenue stream and clinical utility.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Peak Gross Annual Revenue\u003c\/td\u003e\n\u003ctd\u003eExceeded \u003cstrong\u003e$25 million\u003c\/strong\u003e annually when first introduced\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Annual Gynecologic Cancer Diagnoses\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e115,000\u003c\/strong\u003e new cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Annual Gynecologic Cancer Diagnoses\u003c\/td\u003e\n\u003ctd\u003eEstimated \u003cstrong\u003e250,000\u003c\/strong\u003e cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Drug Response Prediction Accuracy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92% accuracy\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemoFx® Testing Turnaround Time\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28-35 days\u003c\/strong\u003e after tissue receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; personalized diagnostic assays exist, but this one is validated and integrated with their AI.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAI platform scientifically validated against \u003cstrong\u003e175\u003c\/strong\u003e FDA-approved drugs and \u003cstrong\u003e130\u003c\/strong\u003e primary samples from ovarian tumors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; competitors can develop similar assays, but imitation requires replicating the underlying data and validation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUnderlying data asset: Biobank contains approximately \u003cstrong\u003e150,000\u003c\/strong\u003e live cell tumor samples.\u003c\/li\u003e\n\u003cli\u003eGynecological cancer specimens comprise nearly half of the biobank.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; they are actively pushing for European launch and US expansion, showing clear commercial focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnnounced planned launch of ChemoFx® in \u003cstrong\u003eEurope\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDiscussions underway to expand adoption in the \u003cstrong\u003eU.S.\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, dependent on continued clinical validation and market adoption against emerging diagnostics.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e5. Drug Repurposing Data Registry\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a pipeline for low-cost drug development by identifying new uses for abandoned compounds (like Afuresertib for breast cancer), potentially speeding up time-to-market.\u003c\/p\u003e\n\u003cp\u003eThe drug repurposing initiative has demonstrated accelerated timelines, with the platform eliminating at least \u003cstrong\u003e18 months\u003c\/strong\u003e of wet lab testing in initial screenings. The screening process for identifying promising candidates was completed in under \u003cstrong\u003e12 weeks\u003c\/strong\u003e. This capability is set against a backdrop where the market for repurposed drugs is projected to grow to \u003cstrong\u003e$51.8 billion\u003c\/strong\u003e by 2033, up from \u003cstrong\u003e$32.1 billion\u003c\/strong\u003e in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the process of systematically screening abandoned drugs using AI is less common than standard de novo discovery.\u003c\/p\u003e\n\u003cp\u003eThe proprietary biobank supporting this initiative contains more than \u003cstrong\u003e150,000\u003c\/strong\u003e heterogenous human tumor samples. In one instance, by precisely measuring only \u003cstrong\u003e92\u003c\/strong\u003e combinations of laboratory experiments, the predictive model made an additional \u003cstrong\u003e964\u003c\/strong\u003e confident predictions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the specific screening methodology and the resulting list of identified compounds are proprietary knowledge.\u003c\/p\u003e\n\u003cp\u003eThe scientifically validated AI platform, PEDAL, is able to predict if a tumor sample will respond to a certain drug compound with \u003cstrong\u003e92%\u003c\/strong\u003e accuracy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; they are actively expanding this approach, showing commitment to monetizing this data asset.\u003c\/p\u003e\n\u003cp\u003eThe organization has shown commitment by running its platform for just \u003cstrong\u003eeight weeks\u003c\/strong\u003e to identify compounds. The company reported a loss from continuing operations of approximately \u003cstrong\u003e$2.3 million\u003c\/strong\u003e on total revenue of \u003cstrong\u003e$110,310\u003c\/strong\u003e for the first quarter of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the pool of publicly known abandoned drugs is finite, and competitors could replicate the screening.\u003c\/p\u003e\n\u003cp\u003eKey results from the drug repurposing registry include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCompound\u003c\/th\u003e\n\u003cth\u003eInhibitor Type\u003c\/th\u003e\n\u003cth\u003eTumor Types with Strong Results\u003c\/th\u003e\n\u003cth\u003eOutperformed Standard of Care\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfuresertib\u003c\/td\u003e\n\u003ctd\u003eAkt Inhibitor\u003c\/td\u003e\n\u003ctd\u003eOvarian and Colon\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlisertib\u003c\/td\u003e\n\u003ctd\u003eAurora A Inhibitor\u003c\/td\u003e\n\u003ctd\u003eOvarian and Colon\u003c\/td\u003e\n\u003ctd\u003eOxaliplatin (Colon); Ribociclib (Breast)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntinostat\u003c\/td\u003e\n\u003ctd\u003eHDAC1\/3 Inhibitor\u003c\/td\u003e\n\u003ctd\u003eOvarian and Colon\u003c\/td\u003e\n\u003ctd\u003eOxaliplatin (Colon)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe initial screening identified \u003cstrong\u003ethree\u003c\/strong\u003e compounds warranting further exploration. The platform was able to cover a total of \u003cstrong\u003e79%\u003c\/strong\u003e of all possible experiments in the initial test set.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's biobank size is over \u003cstrong\u003e150,000\u003c\/strong\u003e assay-capable heterogenous human tumor samples.\u003c\/li\u003e\n\u003cli\u003eThe Q3 2025 revenue was reported as \u003cstrong\u003e$3,618\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Stockholder's Deficit as of September 30, 2025, was \u003cstrong\u003e$77.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e6. Digital Asset Treasury (ATH Token Holdings)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe digital asset treasury strategy, centered on the Aethir (ATH) token, represents a significant, non-core component of Predictive Oncology's financial structure as of late 2025.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAs of \u003cstrong\u003eNovember 10, 2025\u003c\/strong\u003e, the Company held approximately \u003cstrong\u003e5.70 billion ATH\u003c\/strong\u003e tokens, with a market value of approximately \u003cstrong\u003e$152.8 million\u003c\/strong\u003e, based on a price of \u003cstrong\u003e$0.0268\u003c\/strong\u003e per ATH. Of this holding, \u003cstrong\u003e3.7 billion\u003c\/strong\u003e ATH were locked and subject to vesting or transfer restrictions, while \u003cstrong\u003e2.0 billion\u003c\/strong\u003e ATH were unlocked.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe strategy is highly unusual, marking the first time a \u003cstrong\u003eNasdaq\u003c\/strong\u003e-listed company will hold and actively manage tokens from a Decentralized Physical Infrastructure Network (DePIN) as of late 2025.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eImitability is considered high due to the specific market timing, risk tolerance, and strategic alignment required to execute this transaction structure.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe strategy was initiated with two private placement transactions totaling approximately \u003cstrong\u003e$343.5 million\u003c\/strong\u003e. This raise included aggregate cash gross proceeds of approximately \u003cstrong\u003e$50.8 million\u003c\/strong\u003e and in-kind contributions of ATH with an aggregate notional value of approximately \u003cstrong\u003e$292.7 million\u003c\/strong\u003e at the time of signing. The strategy is a core part of the stated financial plan, which also resulted in a \u003cstrong\u003e$74.4 million\u003c\/strong\u003e derivative liability recorded in Q3 2025.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage is temporary, as the valuation is directly subject to the volatile market price of the \u003cstrong\u003eATH\u003c\/strong\u003e token.\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics Related to the Digital Asset Treasury Strategy:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Raise Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$343.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitiation of Strategy (October 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Proceeds from Raise\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitiation of Strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH Notional Value at Signing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$292.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn-kind contribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH Token Holding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.70 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$152.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH Price Used for Valuation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.0268\u003c\/strong\u003e per ATH\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocked ATH Tokens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnlocked ATH Tokens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDerivative Liability (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRelated to ATH strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (End Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$181,667\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContinuing operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's operational structure and financial health metrics surrounding this strategy include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBasic and diluted loss per common share from continuing operations for Q3 2025: \u003cstrong\u003e$(107.24)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStockholders' deficit as of September 30, 2025: \u003cstrong\u003e$77.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 operating revenue: \u003cstrong\u003e$3,618\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's biobank contains over \u003cstrong\u003e150,000\u003c\/strong\u003e assay-capable heterogenous human tumor samples.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e7. Decentralized Compute Access Strategy (Aethir Synergy)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures access to decentralized GPU networks via ATH token staking\/rentals, aiming to drastically lower the computational cost bottleneck for their AI workloads.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this is a novel, first-mover approach to solving the high CapEx\/OpEx of AI infrastructure in biotech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; it requires a deep, specific partnership with the Aethir ecosystem and the technical know-how to operate as a network node.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this is the explicit reason for the digital asset treasury and the focus of their recent strategic shift.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if they can successfully monetize the reserve through GPU rentals and maintain a cost advantage over traditional cloud providers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Statistical Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Capital Raised via PIPEs\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$344.4 million\u003c\/strong\u003e (Closed October 7, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Proceeds (Cash PIPE)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$50.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNotional Value from Crypto PIPE\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$292.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscounted Value of In-Kind ATH Contribution\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$173.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH Tokens Held (as of November 10, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e5.70 billion ATH\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Value of ATH Holdings (Nov 10, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$152.8 million\u003c\/strong\u003e (at $0.0268\/ATH)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocked ATH Tokens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnlocked ATH Tokens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAethir Network Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGPU Network Scale: \u003cstrong\u003e435,000 GPU containers\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGlobal Footprint: Across \u003cstrong\u003e200+ locations\u003c\/strong\u003e in \u003cstrong\u003e93 countries\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eClaimed Cost Savings vs. Traditional Providers: \u003cstrong\u003e40–80%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAethir Q3 Revenue: Over \u003cstrong\u003e$39.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAethir Total ARR: Skyrocketing to \u003cstrong\u003e$166 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eATH Token Incentive: Additional \u003cstrong\u003e20%\u003c\/strong\u003e ATH granted for each open market purchase by POAI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe strategy establishes the world's first Strategic Compute Reserve.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e8. Proprietary Multi-Omic Survival Prediction Models\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMulti-omic machine learning (ML) models demonstrated superior prediction of short-term (two-year) and long-term (five-year) survival outcomes compared to clinical data alone in the UPMC Magee-Womens Hospital study.\u003c\/li\u003e\n\u003cli\u003eThe PEDAL platform demonstrated the ability to predict drug response with 92% accuracy.\u003c\/li\u003e\n\u003cli\u003eThe UPMC study incorporated multi-omic data from 235 ovarian cancer patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe proprietary biobank contains over 150,000 tumor samples spanning 137 tumor types.\u003c\/li\u003e\n\u003cli\u003eThe models utilized feature sets including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), drug response profile, and digital pathology profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eA Proof of Concept (PoC) study utilized the ML model to make 4,600 drug\/tumor type predictions based on 720 hands-on experiments.\u003c\/li\u003e\n\u003cli\u003eThe PoC study involved hands-on testing of 175 FDA-approved drugs using 130 ovarian tumor samples.\u003c\/li\u003e\n\u003cli\u003eThe training of 160 multi-omic ML models was completed in 11 weeks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company reported entry into the biomarker discovery market, estimated at $51.5 billion in 2024, following the development of the ovarian cancer models.\u003c\/li\u003e\n\u003cli\u003eThe company implemented a cost savings initiative expected to reduce cash used in operating activities by 20% annually.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe top-performing models identified different specific drivers for the short- and long-term cohorts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eUPMC Survival Study Cohort\u003c\/th\u003e\n\u003cth\u003ePEDAL PoC Study\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient\/Sample Count\u003c\/td\u003e\n\u003ctd\u003e235 Ovarian Cancer Patients\u003c\/td\u003e\n\u003ctd\u003e130 Ovarian Tumor Samples\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModels Built\/Tested\u003c\/td\u003e\n\u003ctd\u003e160 ML Models Built\u003c\/td\u003e\n\u003ctd\u003e175 FDA-Approved Drugs Tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrediction Accuracy\/Output\u003c\/td\u003e\n\u003ctd\u003eSuperior prediction over clinical data alone\u003c\/td\u003e\n\u003ctd\u003e92% Accuracy Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTimeframe\/Volume\u003c\/td\u003e\n\u003ctd\u003eData analyzed from 2010-2016\u003c\/td\u003e\n\u003ctd\u003e4,600 Predictions Made in 11 Weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePredictive Oncology Inc. (POAI) - VRIO Analysis: \u003cstrong\u003e9. Nasdaq Listing Compliance \u0026amp; Recent Capitalization\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Regaining Nasdaq compliance on \u003cstrong\u003eDecember 1, 2025\u003c\/strong\u003e, preserves access to public markets, while the \u003cstrong\u003e\\$343.5 million\u003c\/strong\u003e raise provides runway to execute the new strategy. Stockholders' equity now exceeds \u003cstrong\u003e\\$2,500,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low; listing compliance is a baseline requirement, but the recent successful raise is a strong positive signal.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; regaining compliance is procedural, but the successful private placement shows investor confidence in the new direction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; CFO Josh Blacher's statement confirms the focus on preserving listing benefits while executing the strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; listing is a prerequisite, and the cash runway is finite; it buys time, it doesn't guarantee success.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance\u003c\/strong\u003e: As of Q3 2025, the net loss was \u003cstrong\u003e\\$77.7 million\u003c\/strong\u003e on revenue of \u003cstrong\u003e\\$3.6 million\u003c\/strong\u003e. Cash position declined to \u003cstrong\u003e\\$182,000\u003c\/strong\u003e from \u003cstrong\u003e\\$612,000\u003c\/strong\u003e in December 2024, with a reported monthly burn rate of \u003cstrong\u003e\\$656,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCapital Raise Component\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate Closed\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal PIPE Raise\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$343.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Component\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$50.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-Kind Crypto Assets (Notional Value)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$292.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-Kind Crypto Assets (Discounted Value)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$173.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOctober 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational and compliance metrics supporting the current financial position include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNasdaq Listing Rule 5550(b)(1) minimum equity threshold: \u003cstrong\u003e\\$2,500,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAI Platform (PEDAL) accuracy in predicting tumor response: \u003cstrong\u003e92%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBiobank size: More than \u003cstrong\u003e150,000\u003c\/strong\u003e assay-capable human tumor samples.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e\\$3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock Price (as of Dec 07, 2025): \u003cstrong\u003e\\$4.2600\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516233605269,"sku":"poai-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/poai-vrio-analysis.png?v=1740207333","url":"https:\/\/dcf-model.com\/products\/poai-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}